DR info

臨床試験数 : 4 / 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 4

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

PLA-PRU-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PLA-PRU-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PRU-PLA-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PRU-PLA-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
Rifaximin
   Ohkubo Hidenori
      2019   Phase 2   JPRN-jRCT2031190137   Japan;
Rifaximin oral tablet
   Yokohama City University
      2019   Phase 2   NCT04118699   Japan;
TD-5108 hydrochloride
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;
THRX-199687 hydrochloride
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;
Velusetrag
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;